Screener
Gyre Therapeutics, Inc. GYRE Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued expenses and other current liabilities | 18,810 | 18,161 |
| Income tax payable | 2,147 | 2,940 |
| Operating lease liabilities, current | 1,385 | 1,119 |
| Total current liabilities | 28,663 | 23,782 |
| Operating lease liabilities, noncurrent | 2,033 | 2,303 |
| Deferred government grants | 829 | 852 |
| Warrant liability, noncurrent | 2,741 | 2,961 |
| Other noncurrent liabilities | 70 | 1,506 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s total current liabilities?
- Gyre Therapeutics, Inc. (GYRE) reported total current liabilities of $28.66M in Q2 2026.
- How has Gyre Therapeutics, Inc.'s total current liabilities changed year-over-year?
- Gyre Therapeutics, Inc.'s total current liabilities increased by 69.4% year-over-year, from $16.92M to $28.66M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Gyre Therapeutics, Inc.'s total current liabilities has grown at a 6.0% compound annual growth rate (CAGR), from $17.8M to $23.78M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Gyre Therapeutics, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude